Drug Trial Radar · NCT05266456
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
Last checked: Nov 19, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
835
Actual
Start
Feb 22, 2022
Primary completion
Jan 10, 2023
Study completion Jan 10, 2023
Sponsor
- Lead sponsor
- Vaxcyte, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
Conditions
- Pneumococcal Vaccines
Interventions
24 valent pneumococcal conjugate vaccineBiological
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
20 valent pneumococcal conjugate vaccineBiological
0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age GroupTime frame: 7 days after vaccination
- Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age GroupTime frame: 7 days after vaccination
- Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age GroupTime frame: 1 month after vaccination
- Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI)Time frame: 6 months after vaccination
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
CenExel RCA
Hollywood, Florida
Precision Clinical Research
Sunrise, Florida
Meridian Clinical Research
Savannah, Georgia
Velocity Clinical Research
Valparaiso, Indiana
Johnson County Clin-Trials
Lenexa, Kansas
Benchmark Research
Metairie, Louisiana
Alliance for Multispecialty Research
Kansas City, Missouri
Rochester Clinical Research
Rochester, New York
Acellacare of Wilmington
Wilmington, North Carolina
Velocity Clinical Research
Warwick, Rhode Island
Coastal Carolina Research
North Charleston, South Carolina
Benchmark Research
San Angelo, Texas
JBR Clinical Research
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.